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What’s in a name? All the world is a stage 
The first requirements of clinical management of prostate cancer are to classify 
patients into prognostic groups and to aid in decision-making on treatment 
options. Of all prognostic factors which determine outcome after prostate cancer 
treatment, the anatomical extent of disease is one of the most important – but 
certainly not the only factor. “Stage”, in truth, means nothing more than the 
anatomical extent of disease.  Unification of clinical staging allows comparison of 
populations and is therefore crucial in public health and epidemiology as well as 
in the design of clinical trials, and routine clinical practice. Careful description of 
the tumor characteristics, on which to build a staging system, is mandatory. The 
TNM-staging is currently considered the cornerstone of tumor classification and 
is regularly updated as novel information provides sufficient evidence to 
underpin a change. Despite its many inconsistencies, TNM as a concept is a 
pragmatic, though imperfect system that has stood the test of time.  
 
To improve outcome prediction, and for clinical management, stage has to be 
combined with other prognostic factors – notably PSA level and Gleason score or 
ISUP grade – to produce a prognostic risk stratification which will ultimately 
determine treatment. A common misconception is that stage (and TNM 
categories) are the same as a prognostic classification. They are not – rather, 
TNM categories (i.e the anatomical extent of diseaese) merely represent a major 
component of prognostic classification. This is acknowledged by both the UICC 
and AJCC versions of the TNM classification for prostate cancer. To combine 
stage with non-anatomical prognostic factors, something further is needed - the 
UICC defines only a stage group, and notes the major non-anatomical factors 
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such as PSA and grade, while the AJCC version has what they term  a “prognostic 
stage group” classification, which (like the d’Amico risk classification) overtly 
incorporates factors other than extent of disease. The EAU Guidelines 
recommend following the UICC version of the classification, and it is important 
for public health and epidemiology not to confuse “stage” and “prognostic stage 
group”. 
 
Imaging for extent of primary disease 
 
Across the world, and across all cancer sites, there is variation in the way in 
which imaging is performed to assess tumour extent. In the case of lung cancer, 
for example, information from cross-sectional imaging can be used to help define 
a clinical T or N category. In the case of prostate cancer, prostate imaging was 
often incorporated in the clinical T category, but this introduces many 
inconsistencies. Firstly, there are great variations in the availability, quality, and 
expertise brought to bear on prostate imaging (for example with 
multiparametric MRI).  Secondly, while modern imaging will identify patients 
who, for example, have subtle and early evidence of extraprostatic extension, 
these patients are manifestly different to patients with gross evidence of 
extraprostatic extension that is palpable by DRE. Simply calling them both “cT3” 
is an example of stage migration, and will mean that the radiologically staged 
patients have a far better prognosis and (arguably) might be over-treated 
compared with those whose locally advanced disease is clinically palpable. This 
is why, for the 8th edition of TNM,  imaging is no longer used for the definition of 
T-category of prostate cancers1.  
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What you record, and what you use, need not be the same as what you 
report to the cancer registry 
The new EAU Prostate cancer-guidelines for 2019 now recommend mpMRI early 
in the diagnosis of prostate cancer, even before doing the first biopsy. Early 
diagnosis and possibly accurate delineation of the intraprostatic extent of 
prostate cancer can be improved by mpMRI2,3. Should mpMRI findings be 
incorporated into future editions of TNM? Perhaps the time will come when 
advanced imaging is widely available, and when the precise delineation of 
intraprostatic disease volume makes a crucial difference to local treatment 
wordwide, but for organ-confined disease at least, it is unlikely to impact in a 
major way on overall survival, when other factors such as PSA and ISUP grade 
are accounted for. The sensitivity of mpMRI to identify microscopic 
extracapsular growth is low but mpMRI is superior in predicting established 
extracapsular growth on histology compared to nomograms and clinical staging4. 
Current nomograms include clinical T-stage mainly based on DRE 5-7 and 
therefore incorrect prediction may be obtained when MRI is included in T-
staging. Nomogram histological outcome prediction, however, can be improved 
by separately adding mpMRI data8. A radiologic-risk signature based on mpMRI 
was a better predictor of biochemical recurrence after prostatectomy when 
compared to the classic Kattan nomogram9 and using mpMRI instead of DRE for 
clinical staging improved the prediction of nodal metastases10. Therefore, 
recording the extent of disease in the prostate assessed on mpMRI, is perfectly 
justifiable, but if used should be added in a descriptive format rather than 
assigning and reporting a T-category based on it. It is important to distinguish 
 5 
between what is reported, for example if UICC TNM stage is used for public 
health surveillance, and what is used, for example in daily practice. The exclusion 
of imaging from cT categorisation in no way means that imaging should not be 
done, or that the information should not be used for clinical decision making. It 
should be remembered that UICC TNM is intended to be used worldwide; 
however, sophisticated imaging such as mpMRI is most certainly not yet 
available worldwide. 
 
An additional argument for routine prostate imaging in clinical practice is that 
with DRE, only the dorsal side of the prostate can be reliably palpated. Therefore, 
inclusion of imaging information  from mpMRI alongside T-categorisation has 
the potential to improve accuracy of clinical assessment, especially where there 
is an anterior tumour. Again, though, such findings from imaging modalities 
should be used but reported as a description of the observations, rather than 
using them to assign and report a T-category. 
 
 
Conclusions 
The EAU Prostate cancer guidelines give specific recommendations about when 
to use imaging, and what sort of imaging to use. We must neither expect TNM to 
be a one-stop repository for all staging information nor should we imply that 
patients should only have those assessments done which feature in the TNM 
classification.  
 Confusion undoubtedly exists regarding the use of imaging data in 
defining and recording T-category. This article is written to draw attention to 
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this and to stress the importance of a uniform approach to T-category 
assignment. Image the prostate with modern MRI by all means, and use the 
results in clinical management, but only the DRE result should be recorded for 
assigning a TNM clinical stage. 
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